SC
PTGX icon

Samlyn Capital’s Protagonist Therapeutics PTGX Stock Holding History

Samlyn Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-448,908
Closed -$15.4M – 135
2021
Q4 		$15.4M Buy
+448,908
New +$14.2M 0.21% 86

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Samlyn Capital's PTGX Position: Q1 2022 in Review

Samlyn Capital sold out of Protagonist Therapeutics (PTGX) in Q1 2022, closing a stake of 448,908 shares — an estimated $15.4M sold.

Samlyn Capital first reported a position in PTGX in Q4 2021 and held it in 1 quarter. The position peaked at $15.4M in Q4 2021. 140 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

  • Samlyn Capital reported no remaining Protagonist Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Samlyn Capital sold 448,908 Protagonist Therapeutics shares in Q1 2022, an estimated $15.4M.
  • Samlyn Capital first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 1 quarter.
  • Samlyn Capital's Protagonist Therapeutics position peaked at $15.4M in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on Samlyn Capital's 13F filing for Q1 2022, filed 16 May 2022.